Macular Degeneration Drug Pipeline Analysis Report 2025

A study conducted in 2022 revealed that around 19.83 million Americans were affected by some form of age-related macular degeneration (AMD). Out of these, around 1.49 million people were affected by late-stage AMD. The prevalence of developing the condition increases with age. It rises from 2% (for people aged 40 to 44 years) to 46.6% (for people aged above 85). As the global geriatric population is growing, the demand for high-efficacy macular degeneration drugs is on the rise. This has prompted major healthcare institutions to develop new drugs, resulting in an increased number of drugs in the pipeline.

Report Coverage

The Macular Degeneration Drug Pipeline Insight Report by the publisher gives comprehensive insights into macular degeneration therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for macular degeneration. The macular degeneration report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The macular degeneration pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with macular degeneration treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to macular degeneration.

Macular Degeneration Drug Pipeline Outlook

Age-related macular degeneration (AMD) is a condition which damages a part of the retina (macula), leading to loss of central vision. It is commonly divided into two categories, namely, dry AMD and wet AMD. Dry age-related macular degeneration involves thinning of the macula with age and formation of drusen (small protein clumps). It is more common as compared to wet AMD. The American Academy of Ophthalmology reports that 8 out of 10 people are affected by dry AMD. Although less common, wet AMD is considered to be more serious as vision loss is faster in comparison to dry AMD. It involves the growth of new and abnormal blood vessels under the retina. These blood vessels may leak and scar the macula significantly.

Macular degeneration treatment involves the use of anti-VEGF therapies, which work by inhibiting abnormal vessel growth and decreasing the chance of fluid leakage. Photodynamic therapy and laser photocoagulation can also be used based on patient profiles. In 2023, two new drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) received the U.S. FDA’s approval for geographic atrophy (a late stage of dry AMD) treatment. These intravenous drugs slowed disease progression by about 14% to 20%.

For years, patients have been limited to using AREDS2 vitamins for treating intermediate stages of dry AMD. However, the approval of new drugs elevates hope for both patients and healthcare professionals to manage the condition more efficiently.

Macular Degeneration - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of macular degeneration drug candidates based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The pipeline assessment report covers 50+ drug analyses based on drug classes:

• Anti-VEGF (Vascular Endothelial Growth Factor) Agents
• Anti-Inflammatory Agents
• Complement Inhibitors

By Route of Administration

The macular degeneration report assessment covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Macular Degeneration - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials conducted, with over 550 macular degeneration emerging drugs undergoing clinical development.

Macular Degeneration - Pipeline Assessment Segmentation, By Drug Class

The drug class categories covered under macular degeneration pipeline analysis include anti-VEGF (vascular endothelial growth factor) agents, anti-inflammatory agents (corticosteroids), complement inhibitors and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials. According to analysis, gene therapy, stem cell therapy and other photodynamic therapies are under investigation and likely to impact the drug class landscape significantly in coming years.

Macular Degeneration Clinical Trials Assessment - Competitive Dynamics

The report for the macular degeneration drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed macular degeneration therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in macular degeneration clinical trials:

• CHABiotech CO., Ltd
• F. Hoffmann-La Roche AG
• GSK Plc.
• Allegro Ophthalmics, LLC
• Bayer AG
• IVERIC Bio, Inc.
• Allergan Inc.
• Others

Macular Degeneration - Emerging Drugs Profile

GT005

This investigational gene therapy is currently under phase 2 clinical trials of a program initiated by The Department of Ophthalmology at Columbia University Irving Medical Center. It acts on the complement factor I (CFI) protein that inhibits the immune system from attacking the retina cells. This intravenous drug intended to treat geographic atrophy secondary to dry age-related macular degeneration has also received Fast-Track Designation from the United States FDA.

Ixo-vec

Developed by Adverum Biotechnologies Inc., this macular degeneration drug candidate showed efficacy in over 90% of the subjects in the LUNA Phase 2 trial. This trial involves 60 patients with wet AMD and is divided across two dose cohorts 2E11 and 6E10 vg/eye. Both doses involved showed visual as well as anatomic outcomes, signifying its efficacy.

4D-150

4D Molecular Therapeutics’ wet AMD drug candidate 4D-150 showed positive outcomes in Phase 2 PRISM clinical trial. This trial evaluated the safety, durability, and suitability of the drug. The company aims to present the drug for Phase 3 and apply for FDA RMAT and EMA PRIME designations as well.

CT-1812

Sponsored by Cognition Therapeutics, this drug is under evaluation to treat late-stage dry AMD. CT-1812 is a small-molecule oral medication that has the potential to cross the blood-retinal barrier and reach the back of the retina without injection intervention. The drug will be evaluated on 246 patients as a part of the Phase 2 MAGNIFY study.

Reasons To Buy This Report

The Macular Degeneration Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for macular degeneration. It provides the necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities provided by the macular degeneration drug report.

Key Questions Answered in the Macular Degeneration - Pipeline Assessment Report

• What is the current landscape of systemic macular degeneration drugs?
• Which companies/institutions are developing macular degeneration therapeutic drugs?
• How many phase II drugs are currently present in macular degeneration pipeline drugs?
• Which company is leading the macular degeneration pipeline development activities?
• What is the current macular degeneration commercial assessment?
• What are the opportunities and challenges present in the macular degeneration drug pipeline landscape?
• What is the efficacy and safety profile of macular degeneration pipeline drugs?
• Which companies/institutions are involved in macular degeneration collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What geographies are covered for clinical trials in macular degeneration?

This product will be delivered within 3-5 business days.